1. Etanercept as a rescue agent in patient with adult onset Still's disease complicated with congestive heart failure
- Author
-
Tsung-Yun Ho, San-Yuan Kuo, Chen-Hung Chen, Kang-Min Lin, Jenn-Haung Lai, Deng-Ho Yang, and Deh-Ming Chang
- Subjects
medicine.medical_specialty ,Myocarditis ,Immunology ,Arthritis ,Disease ,Receptors, Tumor Necrosis Factor ,Etanercept ,Ventricular Dysfunction, Left ,Young Adult ,Rheumatology ,Internal medicine ,medicine ,Sore throat ,Immunology and Allergy ,Humans ,Glucocorticoids ,Heart Failure ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Recovery of Function ,medicine.disease ,Rash ,Treatment Outcome ,Heart failure ,Immunoglobulin G ,Ferritins ,Cardiology ,Cyclosporine ,Drug Therapy, Combination ,Female ,Radiography, Thoracic ,medicine.symptom ,business ,Still's Disease, Adult-Onset ,Immunosuppressive Agents ,medicine.drug - Abstract
Adult onset Still’s disease (AOSD) is an uncommon disorder of unknown cause. The clinical symptoms of AOSD are a spiking fever, a typical rash, arthralgia or arthritis, sore throat, lymphadenopathy, and splenomegaly. Pleuropulmonary and cardiac involvement are rare. We report a patient with a two-year history of AOSD with myocarditis refractory to cyclosporine and glucocorticoid. Significant congestive heart failure due to left ventricle dysfunction and hyperferritinemia developed during the hospital course. After therapy with etanercept, the patient’s clinical manifestations recovered and she regained normal left ventricular systolic function.
- Published
- 2008